Moderna Stock - Long-term strategy in focus after mRNA flu progress

Edited by ad hoc news Long-Term & Business-Model Desk. Verified prior to publication on 06/20/2026, 16:18 CET. Details in the imprint.

Moderna (US60770K1034) is steadily reframing its story from pandemic winner to diversified vaccine and oncology player. The company outlines a multi-year plan to build a portfolio of respiratory, latent virus and cancer vaccines that could support billions in annual revenue according to recent investor presentations.

Pipeline built for the next decade

Moderna’s management highlights a late-stage pipeline that now includes respiratory vaccines for COVID-19, RSV and influenza, along with programs targeting latent viruses such as CMV and EBV. The company also advances personalized cancer vaccines in collaboration with Merck.

According to recent analysis based on Nasdaq data, Jefferies reiterated a Hold rating and a $45 price target after a US FDA advisory committee voted 9-0 in favor of full approval for Moderna’s mRNA flu vaccine mFLUSIVA in adults 50-64 and 9-0 for accelerated approval in adults 65 and over.

How Moderna frames its long-term strategy

In public comments and investor materials, Moderna outlines a strategy centered on its mRNA platform, scaled manufacturing and digital capabilities, aiming to launch multiple vaccines and therapeutics annually over the coming years. It targets sustainable profitability once its next wave of products matures.

The company has acknowledged billions in expected losses in the near term as COVID-19 revenues normalize and R&D spending stays high, but it argues that ongoing investment is necessary to build a durable franchise across infectious diseases and oncology.

The product behind the stock

Moderna is best known for its COVID-19 vaccine Spikevax, but its portfolio now extends to late-stage candidates such as mFLUSIVA, an mRNA-based seasonal influenza vaccine designed to protect adults against multiple flu strains using the same technology platform.

Where the stock trades today

Moderna shares (US60770K1034) trade on the Nasdaq at $63.96 as of 06/20/2026, 14:00 UTC, based on recent market data.

This article was AI-assisted and editorially reviewed. Price and company data without warranty; prices and dates may change at short notice. No investment advice, no buy or sell recommendation. Trading securities involves risk up to total loss of capital.